Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gerard Pals is active.

Publication


Featured researches published by Gerard Pals.


The Lancet | 1995

Long-term sequelae of Helicobacter pylori gastritis.

E. J. Kuipers; A.S. Peña; H.P.M. Festen; Stephan G. M. Meuwissen; A.M. Uyterlinde; R. Roosendaal; Gerard Pals; G.F. Nelis

Chronic Helicobacter pylori gastritis has been put forward as a risk factor for development of gastric mucosal atrophy and gastric cancer. The purpose of our study was to investigate the long-term effects of H pylori gastritis on the gastric mucosa. We prospectively studied 49 subjects negative for H pylori and 58 positive subjects for a mean follow-up of 11.5 years (range 10-13 years). Serum samples were obtained at the initial and follow-up visits for determination of H pylori IgG antibodies. Gastroscopies with biopsy sampling were done in all patients at both visits. Biopsy specimens were used for assessment of H pylori infection and histology. Development of atrophic gastritis and intestinal metaplasia occurred in 2 (4%) uninfected and 16 (28%) infected subjects. Regression of atrophy was noted in 4 (7%) infected subjects. Development of atrophic gastritis and intestinal metaplasia was significantly associated with H pylori infection (p = 0.0014; odds ratio 9.0, 95% CI 1.9-41.3). The proportion of atrophic gastritis in the study population showed an annual increase of 1.15% (0.5-1.8%). We conclude that H pylori infection is a significant risk factor for development of atrophic gastritis and intestinal metaplasia. Our findings support strongly the causative role of this infection in gastric carcinogenesis.


The Journal of Pathology | 2001

Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer

Jurgen M.J. Piek; Paul J. van Diest; Ronald P. Zweemer; Jan W. Jansen; Ria J.J. Poort-Keesom; Fred H. Menko; Johan J. P. Gille; Ans P. M. Jongsma; Gerard Pals; P. Kenemans; René H.M. Verheijen

The aim of this study was to investigate the occurrence of (pre)neoplastic lesions in overtly normal Fallopian tubes from women predisposed to developing ovarian carcinoma. The presence of (pre)neoplastic lesions was scored in histological specimens from 12 women with a genetically determined predisposition for ovarian cancer, of whom seven tested positive for a germline BRCA1 mutation. A control group included 13 women. Immunohistochemistry was used to determine the expression of p21, p27, p53, cyclin A, cyclin D1, bcl‐2, Ki67, HER‐2/neu, and the oestrogen and progesterone receptors. Loss of heterozygosity (LOH) analysis on the BRCA1 locus was also assessed on dysplastic tissue by PCR studies. Of the 12 women with a predisposition for ovarian cancer, six showed dysplasia, including one case of severe dysplasia. Five harboured hyperplastic lesions and in one woman no histological aberrations were found in the Fallopian tube. No hyperplastic, dysplastic or neoplastic lesions were detected in the Fallopian tubes of control subjects. In the cases studied, morphologically normal tubal epithelium contained a higher proportion of Ki67‐expressing cells (p=0.005) and lower fractions of cells expressing p21 (p<0.0001) and p27 (p=0.006) than in the control group. Even higher fractions of proliferating cells were found in dysplastic areas (p=0.07) and accumulation of p53 was observed in the severely dysplastic lesion. Expression patterns of other proteins studied, including the hormone receptors, were similar in cases and controls. One subject, a germline BRCA1 mutation carrier, showed loss of the wild‐type BRCA1 allele in the severely dysplastic lesion. In conclusion, the Fallopian tubes of women predisposed to developing ovarian cancer frequently harbour dysplastic changes, accompanied by changes in cell‐cycle and apoptosis‐related proteins, indicating an increased risk of developing tubal cancer. Copyright


Nature Genetics | 2011

Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis

Ingrid van de Laar; Rogier A. Oldenburg; Gerard Pals; Jolien W. Roos-Hesselink; Bianca M. de Graaf; Judith M.A. Verhagen; Yvonne M. Hoedemaekers; Rob Willemsen; Lies-Anne Severijnen; Hanka Venselaar; Gert Vriend; Peter M. T. Pattynama; Margriet J. Collee; Danielle Majoor-Krakauer; Don Poldermans; Ingrid M.E. Frohn-Mulder; Dimitra Micha; Janneke Timmermans; Yvonne Hilhorst-Hofstee; Sita M. A. Bierma-Zeinstra; Patrick J. Willems; Johan M. Kros; Edwin H. G. Oei; Ben A. Oostra; Marja W. Wessels; Aida M. Bertoli-Avella

Thoracic aortic aneurysms and dissections are a main feature of connective tissue disorders, such as Marfan syndrome and Loeys-Dietz syndrome. We delineated a new syndrome presenting with aneurysms, dissections and tortuosity throughout the arterial tree in association with mild craniofacial features and skeletal and cutaneous anomalies. In contrast with other aneurysm syndromes, most of these affected individuals presented with early-onset osteoarthritis. We mapped the genetic locus to chromosome 15q22.2–24.2 and show that the disease is caused by mutations in SMAD3. This gene encodes a member of the TGF-β pathway that is essential for TGF-β signal transmission. SMAD3 mutations lead to increased aortic expression of several key players in the TGF-β pathway, including SMAD3. Molecular diagnosis will allow early and reliable identification of cases and relatives at risk for major cardiovascular complications. Our findings endorse the TGF-β pathway as the primary pharmacological target for the development of new treatments for aortic aneurysms and osteoarthritis.


Nature Genetics | 2005

The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J.

Marieke Levitus; Quinten Waisfisz; Barbara C. Godthelp; Yne de Vries; Shobbir Hussain; Wouter W. Wiegant; Elhaam Elghalbzouri-Maghrani; Jurgen Steltenpool; Martin A. Rooimans; Gerard Pals; Fré Arwert; Christopher G. Mathew; Małgorzata Z. Zdzienicka; Kevin Hiom; Johan P. de Winter; Hans Joenje

The protein predicted to be defective in individuals with Fanconi anemia complementation group J (FA-J), FANCJ, is a missing component in the Fanconi anemia pathway of genome maintenance. Here we identify pathogenic mutations in eight individuals with FA-J in the gene encoding the DEAH-box DNA helicase BRIP1, also called FANCJ. This finding is compelling evidence that the Fanconi anemia pathway functions through a direct physical interaction with DNA.


Nature Genetics | 2007

Fanconi anemia is associated with a defect in the BRCA2 partner PALB2

Bing Xia; Josephine C. Dorsman; Najim Ameziane; Yne de Vries; Martin A. Rooimans; Qing Sheng; Gerard Pals; Abdellatif Errami; Eliane Gluckman; Julián Llera; Weidong Wang; David M. Livingston; Hans Joenje; Johan P. de Winter

The Fanconi anemia and BRCA networks are considered interconnected, as BRCA2 gene defects have been discovered in individuals with Fanconi anemia subtype D1. Here we show that a defect in the BRCA2-interacting protein PALB2 is associated with Fanconi anemia in an individual with a new subtype. PALB2-deficient cells showed hypersensitivity to cross-linking agents and lacked chromatin-bound BRCA2; these defects were corrected upon ectopic expression of PALB2 or by spontaneous reversion.


The Lancet | 1993

Seroconversion for Helicobacter pylori

E. J. Kuipers; A.S. Peña; N.F.M Pels; E. Kurz-Pohlmann; Stephan G. M. Meuwissen; G van Kamp; A.M. Uyterlinde; Gerard Pals

The prevalence of Helicobacter pylori antibodies increases with age, but it is unknown whether this is due to a constant rate of infection in different age groups, or whether most infection occurs in childhood. Follow-up data on infection rates and the course of infection in an untreated population are scarce. We measured H pylori IgG antibody concentrations in patients who were seen at our endoscopy unit between 1979 and 1983. 115 of 164 eligible patients (70%) participated in the study. H pylori IgG antibody concentrations were measured in two serum samples taken with a mean interval of 11.5 years. 56 patients tested positive at the first visit. During follow-up, 2 patients became infected (annual infection rate 0.30%, 95% Cl 0.04-1.08%). Evidence of infection disappeared in 6 patients: after gastric surgery in 3 and due to an unknown cause in the remaining 3 patients. A non-significant decrease of infection was shown in different age cohorts during follow-up. Antibody concentrations did not increase with age. These results strongly support the concept of dominant infection rates in childhood. Elimination of infection may occur in a few patients without eradication therapy.


American Journal of Human Genetics | 2009

PPIB Mutations Cause Severe Osteogenesis Imperfecta

Fleur S. van Dijk; Isabel M. Nesbitt; Eline H. Zwikstra; Peter G. J. Nikkels; Sander R. Piersma; Silvina A. Fratantoni; Connie R. Jimenez; Margriet Huizer; Alice C. Morsman; Jan Maarten Cobben; Mirjam H.H. van Roij; Mariet W. Elting; Jonathan I.M.L. Verbeke; Liliane C. D. Wijnaendts; Nick Shaw; Wolfgang Högler; Carole McKeown; Erik A. Sistermans; Ann Dalton; Hanne Meijers-Heijboer; Gerard Pals

Deficiency of cartilage-associated protein (CRTAP) or prolyl 3-hydroxylase 1(P3H1) has been reported in autosomal-recessive lethal or severe osteogenesis imperfecta (OI). CRTAP, P3H1, and cyclophilin B (CyPB) form an intracellular collagen-modifying complex that 3-hydroxylates proline at position 986 (P986) in the alpha1 chains of collagen type I. This 3-prolyl hydroxylation is decreased in patients with CRTAP and P3H1 deficiency. It was suspected that mutations in the PPIB gene encoding CyPB would also cause OI with decreased collagen 3-prolyl hydroxylation. To our knowledge we present the first two families with recessive OI caused by PPIB gene mutations. The clinical phenotype is compatible with OI Sillence type II-B/III as seen with COL1A1/2, CRTAP, and LEPRE1 mutations. The percentage of 3-hydroxylated P986 residues in patients with PPIB mutations is decreased in comparison to normal, but it is higher than in patients with CRTAP and LEPRE1 mutations. This result and the fact that CyPB is demonstrable independent of CRTAP and P3H1, along with reported decreased 3-prolyl hydroxylation due to deficiency of CRTAP lacking the catalytic hydroxylation domain and the known function of CyPB as a cis-trans isomerase, suggest that recessive OI is caused by a dysfunctional P3H1/CRTAP/CyPB complex rather than by the lack of 3-prolyl hydroxylation of a single proline residue in the alpha1 chains of collagen type I.


Breast Cancer Research and Treatment | 2007

BRCA1 and BRCA2 germline mutation analysis in the Indonesian population

Dewajani Purnomosari; Gerard Pals; Artanto Wahyono; Teguh Aryandono; Tjakra Wibawa Manuaba; Samuel J Haryono; Paul J. van Diest

Specific mutations in BRCA1 and BRCA2 genes have been identified in specific populations and ethnic groups. However, little is known about the contribution of BRCA1 and BRCA2 mutations to breast cancers in the Indonesian population. One hundred-twenty moderate to high risk breast cancer patients were tested using PCR-DGGE, and any aberrant band was sequenced. Multiplex ligation-dependent probe amplification (MLPA) was performed on all samples to detect large deletions in the two genes. Twenty-three different mutations were detected in 30 individuals, ten were deleterious mutations and 20 were “unclassified variants” with uncertain clinical consequences. Three of seven (c.2784_2875insT, p.Leu1415X and del exon 13–15) and two of four (p.Glu2183X and p.Gln2894X) deleterious mutations that were found in BRCA1 and BRCA2 respectively, are novel. Several novel, pathogenic BRCA1 and BRCA2 germline mutations are found in early onset Indonesian breast cancer patients, these may therefore be specific for the Indonesian population.


European Journal of Medical Genetics | 2010

Classification of Osteogenesis Imperfecta revisited.

F. van Dijk; Gerard Pals; R.R. van Rijn; Peter G. J. Nikkels; Jan-Hein Cobben

In 1979 Sillence proposed a classification of Osteogenesis Imperfecta (OI) in OI types I, II, III and IV. In 2004 and 2007 this classification was expanded with OI types V-VIII because of distinct clinical features and/or different causative gene mutations. We propose a revised classification of OI with exclusion of OI type VII and VIII since these types have been added because of genetic criteria (autosomal recessive inheritance) while the clinical and radiological features are indistinguishable from OI types II-IV. Instead, we propose continued use of the Sillence criteria I, II-A, II-B, II-C, III and IV for clinical and radiological classification of OI with additional mentioning of the causative mutated gene to this classification. OI type V and VI are still part of this revised classification, because of the distinguishing clinical/radiological and/or histological features observed in these types.


Journal of Medical Genetics | 2012

Phenotypic spectrum of the SMAD3-related aneurysms–osteoarthritis syndrome

Ingrid van de Laar; Denise van der Linde; Edwin H. G. Oei; P.K. Bos; Johannes H.J.M. Bessems; Sita M. A. Bierma-Zeinstra; Belle L. van Meer; Gerard Pals; Rogier A. Oldenburg; Jos A. Bekkers; Adriaan Moelker; Bianca M. de Graaf; Gabor Matyas; Ingrid M.E. Frohn-Mulder; Janneke Timmermans; Yvonne Hilhorst-Hofstee; Jan Maarten Cobben; Hennie T. Brüggenwirth; Lut Van Laer; Bart Loeys; Julie De Backer; Paul Coucke; Harry C. Dietz; Patrick J. Willems; Ben A. Oostra; Anne De Paepe; Jolien W. Roos-Hesselink; Aida M. Bertoli-Avella; Marja W. Wessels

Background Aneurysms–osteoarthritis syndrome (AOS) is a new autosomal dominant syndromic form of thoracic aortic aneurysms and dissections characterised by the presence of arterial aneurysms and tortuosity, mild craniofacial, skeletal and cutaneous anomalies, and early-onset osteoarthritis. AOS is caused by mutations in the SMAD3 gene. Methods A cohort of 393 patients with aneurysms without mutation in FBN1, TGFBR1 and TGFBR2 was screened for mutations in SMAD3. The patients originated from The Netherlands, Belgium, Switzerland and USA. The clinical phenotype in a total of 45 patients from eight different AOS families with eight different SMAD3 mutations is described. In all patients with a SMAD3 mutation, clinical records were reviewed and extensive genetic, cardiovascular and orthopaedic examinations were performed. Results Five novel SMAD3 mutations (one nonsense, two missense and two frame-shift mutations) were identified in five new AOS families. A follow-up description of the three families with a SMAD3 mutation previously described by the authors was included. In the majority of patients, early-onset joint abnormalities, including osteoarthritis and osteochondritis dissecans, were the initial symptom for which medical advice was sought. Cardiovascular abnormalities were present in almost 90% of patients, and involved mainly aortic aneurysms and dissections. Aneurysms and tortuosity were found in the aorta and other arteries throughout the body, including intracranial arteries. Of the patients who first presented with joint abnormalities, 20% died suddenly from aortic dissection. The presence of mild craniofacial abnormalities including hypertelorism and abnormal uvula may aid the recognition of this syndrome. Conclusion The authors provide further insight into the phenotype of AOS with SMAD3 mutations, and present recommendations for a clinical work-up.

Collaboration


Dive into the Gerard Pals's collaboration.

Top Co-Authors

Avatar

Dimitra Micha

VU University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Fré Arwert

VU University Amsterdam

View shared research outputs
Top Co-Authors

Avatar

Hans Joenje

VU University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Jan C. Pronk

University of Amsterdam

View shared research outputs
Top Co-Authors

Avatar

Janneke Timmermans

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar

Yvonne Hilhorst-Hofstee

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar

J. Defize

University of Amsterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Eric G. Haarman

VU University Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge